The Thyroid-Related Quality of Life Measure ThyPRO Has Good Responsiveness and Ability to Detect Relevant Treatment Effects
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE: Patient-reported outcomes have become important endpoints in comparative effectiveness research and in patient-centered health care. Valid patient-reported outcome measures detect and respond to clinically relevant changes. The purpose of this study was to evaluate responsiveness of the thyroid-related quality of life (QoL) instrument ThyPRO in patients undergoing relevant clinical treatments for benign thyroid diseases and to compare it with responsiveness of the generic SF-36 Health Survey. METHODS: A sample of 435 patients undergoing treatment completed the ThyPRO and SF-36 Health Survey (Version 2) at baseline and 6 months after treatment initiation. Responsiveness was evaluated in three thyroid patient groups: patients with hyperthyroidism (n = 66) and hypothyroidism (n = 84) rendered euthyroid after medical therapy, and patients with a clinically detectable nontoxic goiter treated with surgery or radioactive iodine and remaining euthyroid (n = 62). Changes in QoL were evaluated in terms of effect size and compared to the changes predicted by clinical experts. The responsiveness of equivalent scales from ThyPRO and SF-36 Health Survey were compared with the relative validity index. RESULTS: The ThyPRO demonstrated good responsiveness across the whole range of QoL aspects in patients with hyper- and hypothyroidism. Responsiveness to treatment of nontoxic goiter was also demonstrated for physical and mental symptoms and overall QoL, but not for impact on social life or cosmetic complaints, in contrast to clinicians' predictions. For all comparable scales except one, the ThyPRO was more responsive to treatment than the SF-36 Health Survey. CONCLUSIONS: The ThyPRO was responsive to treatment across the range of benign thyroid diseases. We suggest implementing this measurement instrument as a patient-reported outcome in clinical studies and in clinical management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Validated versions include the full 85-item ThyPRO (64,94–97) and the 39-item ThyPRO-39 scale with the 22-item ThyPRO Composite QoL scale (98).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [95]
In the citing paper
“Additionally, the trials did not use the latest thyroid-specific outcome measures, such as ThyPRO.182”
From Hypothyroidism (2024) · cites this paper as [182]
In the citing paper
“endogenous thyrotoxicosis is well known to have the capability to result in these brain affections (110–112)”
From Levothyroxine therapy in elderly patients with hypothyroidism (2021) · cites this paper as [111]
In the citing paper
“They are not adequately responsive to changes in symptoms and QoL in patients with benign thyroid diseases (25).”
In the citing paper
“There is now a consensus that thyroid specific PROMs, ThyPRO and ThyPRO39 (a shorter version) are the best PROMs for use in RCTs (21, 22, 25).”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
(1992) · PubMed · Cited by 33,716
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Effect Sizes for Interpreting Changes in Health Status
Kazis, L. E., Anderson, J. J., & Meenan, R. F. (1989) · Medical Care · doi:10.1097/00005650-198903001-00015 · Cited by 2,401 · cited 1×
“Magnitude of change was evaluated by standardized effect sizes, calculated as mean difference divided by SD of scores at baseline (39, 40).”
MethodRevicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.012 · Cited by 2,362 · cited 5×
“Impaired Social Life 14 (20) 10 (17) 4 (17) 16 (23) 8 (13) 7 (17) 15 (20) 9 (16) 6 (18) 9 (15) 7 (13) 2 (11)”
BackgroundResultInfluentialPatient reported outcome measures could help transform healthcare
Black, N. (2013) · BMJ · doi:10.1136/bmj.f167 · Cited by 1,960
Generic and Disease-Specific Measures in Assessing Health Status and Quality of Life
Patrick, D. L., & Deyo, R. A. (1989) · Medical Care · doi:10.1097/00005650-198903001-00018 · Cited by 1,790 · cited 2×
“Long academic education (5 y or more) 40 (9) 1 (2) 19 (23) 4 (6)”
Quality of life measurement: bibliographic study of patient assessed health outcome measures
Garratt, A., Schmidt, L., Mackintosh, A., & Fitzpatrick, R. (2002) · BMJ · doi:10.1136/bmj.324.7351.1417 · Cited by 1,192 · cited 4×
“Information not available 13 2 (3) 0 1 (2) Months from treatment initiation to completion of follow-up survey 6.”
BackgroundInfluentialReeve, B. B., Wyrwich, K. W., Wu, A. W., Velikova, G., Terwee, C. B., Snyder, C. F., Schwartz, C., Revicki, D. A., Moinpour, C. M., McLeod, L. D., et al. (2013) · Quality of Life Research · doi:10.1007/s11136-012-0344-y · Cited by 845 · cited 1×
“5) Index treatment L-T4 111 (26) 0 84 (100) 0 Antithyroid medication 86 (20) 36 (55) 0 0 Aspiration of thyroid cyst 4 (1) 0 0 0 Glucocorticoid pulse therapy 2 (0) 0 0 0 Other immunosuppressive treatment 4 (1) 2 (3) 0 0”
Terwee, C. B., Dekker, F. W., Wiersinga, W. M., Prummel, M. F., & Bossuyt, P. M. M. (2003) · Quality of Life Research · doi:10.1023/a:1023499322593 · Cited by 664 · cited 1×
“A very important aspect of the validity of a PRO is whether the instrument can detect relevant clinical changes over time, ie, its responsiveness (11, 37).”
BackgroundSelenium and the Course of Mild Graves' Orbitopathy
Marcocci, C., Kahaly, G. J., Krassas, G. E., Bartalena, L., Prummel, M., Stahl, M., Altea, M. A., Nardi, M., Pitz, S., Boboridis, K., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012985 · Cited by 619
Revicki, D. A., Osoba, D., Fairclough, D., Barofsky, I., Berzon, R., Leidy, N. K., & Rothman, M. (2000) · Quality of Life Research · doi:10.1023/a:1008996223999 · Cited by 577 · cited 2×
“Diagnosis Nontoxic goiter 135 (31) 0 0 51 (82) Toxic nodular goiter 98 (23) 28 (42) 0 11 (18) Graves’ hyperthyroidism 73 (17) 27 (41) 0 0 Graves’ orbitopathy 25 (6) 9 (14) 0 0 Autoimmune hypothyroidism 86 (20) 0 84 (100) 0 Other thyroid diagnosis 18 (4) 2 (3) 0 0 Disease duration, mo 0.”
BackgroundSaravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514 · cited 1×
“Overall QoL impact 40 (34) 22 (28) 18 (32) 43 (35) 17 (26) 26 (34) 40 (36) 19 (26) 21 (33) 32 (29) 23 (28) 8.”
Bonnema, S. J., & Hegedüs, L. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1030 · Cited by 339 · cited 1×
“It is a limitation, however, that the sample size does not allow further subdivision of the effect of various treatments, eg, antithyroid drug treatment, thyroidectomy, and radioactive iodine for hyperthyroidism, which would have profoundly improved our current understanding of evidence-based medicine (52, 53).”
BackgroundSelf-citationPanicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M., & Dayan, C. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1301 · Cited by 327 · cited 7×
“Impaired Social Life 14 (20) 10 (17) 4 (17) 16 (23) 8 (13) 7 (17) 15 (20) 9 (16) 6 (18) 9 (15) 7 (13) 2 (11)”
InfluentialTerwee, C. B., Gerding, M. N., Dekker, F. W., Prummel, M. F., & Wiersinga, W. M. (1998) · British Journal of Ophthalmology · doi:10.1136/bjo.82.7.773 · Cited by 321
Madeley, N. J., Wing, K. J., Topliss, C., Penner, M. J., Glazebrook, M. A., & Younger, A. S. (2012) · Foot & Ankle International · doi:10.3113/fai.2012.0057 · Cited by 235
Quality of life in patients with benign thyroid disorders. A review
Watt, T., Groenvold, M., Rasmussen, A. K., Bonnema, S. J., Hegedüs, L., Bjorner, J. B., & Feldt-Rasmussen, U. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02124 · Cited by 228 · cited 6×
“This makes the measurement of such outcomes particularly relevant in descriptive as well as interventional studies of thyroid diseases, and possibly also in daily clinical management (24).”
BackgroundMethodInfluentialSelf-citationValidity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO
Watt, T., Hegedüs, L., Groenvold, M., Bjorner, J. B., Rasmussen, Å. K., Bonnema, S. J., & Feldt-Rasmussen, U. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0521 · Cited by 210 · cited 6×
“Impaired Sex Life 25 (31) 19 (27) 6 (27) 31 (35) 17 (28) 14 (30) 25 (30) 17 (22) 8 (29) 20 (26) 15 (26) 5 (31)”
MethodInfluentialSelf-citationGuyatt, G. H., King, D. R., Feeny, D. H., Stubbing, D., & Goldstein, R. S. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00157-7 · Cited by 202 · cited 1×
“Therefore, comparisons across diseases can be made, the influence of comorbidity may be better captured, and generic instruments often have substantial documentation of their measurement properties (7).”
BackgroundTerwee, C. B., Dekker, F. W., Mourits, M. P., Gerding, M. N., Baldeschi, L., Kalmann, R., Prummel, M. F., & Wiersinga, W. M. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01241.x · Cited by 202 · cited 5×
“Impaired Sex Life 25 (31) 19 (27) 6 (27) 31 (35) 17 (28) 14 (30) 25 (30) 17 (22) 8 (29) 20 (26) 15 (26) 5 (31)”
BackgroundInfluentialPsychosocial morbidity of Graves’ orbitopathy
Kahaly, G. J., Petrak, F., Hardt, J., Pitz, S., & Egle, U. T. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02352.x · Cited by 184 · cited 1×
“n 435 66 84 62 Gender Women 361 (83) 54 (82) 76 (90) 50 (81) Men 74 (17) 12 (18) 8 (10) 12 (19) Age, y 54 (42–63) 55 (47–65) 45 (32–60) 54 (43–62) Education No vocational training 68 (16) 8 (12) 11 (13) 12 (19) Currently studying 12 (3) 0 7 (8) 3 (5) Short vocational training 52 (13) 15 (23) 7 (8) 9 (15) Apprenticeshi…”
Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism
Fahrenfort, J. J., Wilterdink, A. M. L., & van der Veen, E. A. (2000) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(99)00050-5 · Cited by 144 · cited 2×
“Overall QoL impact 40 (34) 22 (28) 18 (32) 43 (35) 17 (26) 26 (34) 40 (36) 19 (26) 21 (33) 32 (29) 23 (28) 8.”
Eurich, D. T., Johnson, J. A., Reid, K. J., & Spertus, J. A. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-89 · Cited by 134
Long-term effects of Graves' ophthalmopathy on health-related quality of life
Terwee, C., Wakelkamp, I., Tan, S., Dekker, F., Prummel, M., & Wiersinga, W. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460751 · Cited by 120 · cited 5×
“Hypothyroid Symptoms 24 (22) 20 (21) 4 (18) 24 (21) 16 (17) 9 (18) 25 (22) 23 (20) 2 (16) 20 (19) 18 (19) 2 (19)”
InfluentialWatt, T., Bjorner, J. B., Groenvold, M., Rasmussen, Å. K., Bonnema, S. J., Hegedüs, L., & Feldt-Rasmussen, U. (2009) · Quality of Life Research · doi:10.1007/s11136-009-9460-8 · Cited by 112 · cited 6×
“Impaired Sex Life 25 (31) 19 (27) 6 (27) 31 (35) 17 (28) 14 (30) 25 (30) 17 (22) 8 (29) 20 (26) 15 (26) 5 (31)”
MethodInfluentialSelf-citationNovel insights into thyroid hormones from the study of common genetic variation
Dayan, C. M., & Panicker, V. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.19 · Cited by 110 · cited 7×
“Impaired Social Life 14 (20) 10 (17) 4 (17) 16 (23) 8 (13) 7 (17) 15 (20) 9 (16) 6 (18) 9 (15) 7 (13) 2 (11)”
InfluentialTest-Retest Reliability of the GO-QOL
Terwee, C. B., Gerding, M. N., Dekker, F. W., Prummel, M. F., van der Pol, J. P., & Wiersinga, W. M. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00069-4 · Cited by 107
Ware, J. E., Kemp, J. P., Buchner, D. A., Singer, A. E., Nolop, K. B., & Goss, T. F. (1998) · Quality of Life Research · doi:10.1023/a:1024946316424 · Cited by 103
LJUNGGREN, J.-G., TÖRRING, O., WALLIN, G., TAUBE, A., TALLSTEDT, L., HAMBERGER, B., & LUNDELL, G. (1998) · Thyroid · doi:10.1089/thy.1998.8.653 · Cited by 100 · cited 4×
“Long academic education (5 y or more) 40 (9) 1 (2) 19 (23) 4 (6)”
InfluentialEffects of Graves’ ophthalmopathy on quality of life
Wiersinga, W. M., Prummel, M. F., & Terwee, C. B. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03345275 · Cited by 97 · cited 7×
“5) Index treatment L-T4 111 (26) 0 84 (100) 0 Antithyroid medication 86 (20) 36 (55) 0 0 Aspiration of thyroid cyst 4 (1) 0 0 0 Glucocorticoid pulse therapy 2 (0) 0 0 0 Other immunosuppressive treatment 4 (1) 2 (3) 0 0”
InfluentialSaravanan, P., Visser, T. J., & Dayan, C. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0414 · Cited by 90 · cited 6×
“Impaired Social Life 14 (20) 10 (17) 4 (17) 16 (23) 8 (13) 7 (17) 15 (20) 9 (16) 6 (18) 9 (15) 7 (13) 2 (11)”
InfluentialWatt, T., Hegedüs, L., Rasmussen, Å. K., Groenvold, M., Bonnema, S. J., Bjorner, J. B., & Feldt-Rasmussen, U. (2007) · Thyroid · doi:10.1089/thy.2007.0069 · Cited by 89 · cited 4×
“SF-36 scale Physical Function 77 (24) 82 (23) 5 (18) 67 (27) 82 (25) 15 (25) 81 (22) 84 (23) 2 (14) 84 (20) 84 (22) 0 (15)”
MethodInfluentialSelf-citationTreatment of Graves' Hyperthyroidism: Evidence-Based and Emerging Modalities
Hegedűs, L. D. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2009.01.009 · Cited by 85 · cited 1×
“It is a limitation, however, that the sample size does not allow further subdivision of the effect of various treatments, eg, antithyroid drug treatment, thyroidectomy, and radioactive iodine for hyperthyroidism, which would have profoundly improved our current understanding of evidence-based medicine (52, 53).”
BackgroundSelf-citationWatt, T., Rasmussen, Å. K., Grøenvold, M., Bjørner, J. B., Watt, S. K., Bonnema, S. J., Hegedűs, L. D., & Feldt‐Rasmussen, U. (2008) · Quality of Life Research · doi:10.1007/s11136-008-9364-z · Cited by 84 · cited 5×
“5) Index treatment L-T4 111 (26) 0 84 (100) 0 Antithyroid medication 86 (20) 36 (55) 0 0 Aspiration of thyroid cyst 4 (1) 0 0 0 Glucocorticoid pulse therapy 2 (0) 0 0 0 Other immunosuppressive treatment 4 (1) 2 (3) 0 0”
MethodInfluentialSelf-citationWinther, K. H., Watt, T., Bjørner, J. B., Cramon, P., Feldt-Rasmussen, U., Gluud, C., Gram, J., Groenvold, M., Hegedüs, L., Knudsen, N., et al. (2014) · Trials · doi:10.1186/1745-6215-15-115 · Cited by 83
Self-citationSpectrum of quality of life impairment in hypothyroidism
Jaeschke, R., Guyatt, G. H., Cook, D., Harper, S., & Gerstein, H. C. (1994) · Quality of Life Research · doi:10.1007/bf00451724 · Cited by 82
Watt, T., Cramon, P., Bjorner, J., Bonnema, S., Feldt-Rasmussen, U., Gluud, C., Gram, J., Hansen, J., Heged�s, L., Knudsen, N., et al. (2013) · Trials · doi:10.1186/1745-6215-14-119 · Cited by 69 · cited 1×
“To compare higher-order summary measures of the two instruments, responsiveness of a ThyPRO Composite score constructed for two clinical trials (44, 45) was compared with the SF-36 Health Survey Mental Component Summary (MCS).”
MethodSelf-citationMcMillan, C., Bradley, C., Razvi, S., & Weaver, J. U. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00232.x · Cited by 66 · cited 5×
“Hypothyroid Symptoms 24 (22) 20 (21) 4 (18) 24 (21) 16 (17) 9 (18) 25 (22) 23 (20) 2 (16) 20 (19) 18 (19) 2 (19)”
InfluentialQuality of Life and Occupational Disability in Endocrine Orbitopathy
Ponto, K. A., Pitz, S., Pfeiffer, N., Hommel, G., Weber, M. M., & Kahaly, G. J. (2009) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2009.0283 · Cited by 65 · cited 6×
“Eye Symptoms 17 (19) 13 (16) 4 (15) 19 (22) 13 (15) 6 (17) 13 (14) 9 (10) 4 (11) 15 (16) 10 (11) 5 (13) Tiredness 57 (27) 43 (26) 14 (26) 63 (27) 39 (25) 24 (29) 61 (28) 44 (27) 17 (26) 51 (24) 41 (25) 10 (23) Cognition 25 (24) 20 (22) 5 (18) 21 (22) 13 (17) 8 (16) 27 (25) 21 (22) 6 (19) 21 (23) 18 (23) 3 (19) Anxiety…”
InfluentialDattani, R., Slobogean, G. P., O’Brien, P. J., Broekhuyse, H. M., Blachut, P. A., Guy, P., & Lefaivre, K. A. (2012) · Injury · doi:10.1016/j.injury.2012.10.020 · Cited by 63
Deng, N., Allison, J. J., Fang, H., Ash, A. S., & Ware, J. E. (2013) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-11-89 · Cited by 62 · cited 1×
“In addition to this standard approach, calculation of 95% confidence intervals (CIs) around the relative validity index was applied using bootstrapping (43).”
MethodLee, C. F., Luo, N., Ng, R. C. H., Wong, N. S., Yap, Y. S., Lo, S. K., Chia, W. K., Yee, A., Krishna, L. K. R., Wong, C., et al. (2012) · Quality of Life Research · doi:10.1007/s11136-012-0291-7 · Cited by 47
Tehrani, M., Krummenauer, F., Mann, W. J., Pitz, S., Dick, H. B., & Kahaly, G. J. (2004) · European Journal of Ophthalmology · doi:10.1177/112067210401400302 · Cited by 40 · cited 2×
“Impaired Sex Life 25 (31) 19 (27) 6 (27) 31 (35) 17 (28) 14 (30) 25 (30) 17 (22) 8 (29) 20 (26) 15 (26) 5 (31)”
Abraham‐Nordling, M., Wallin, G., Lundell, G. E. F., & Törring, O. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02336 · Cited by 39 · cited 5×
“Hypothyroid Symptoms 24 (22) 20 (21) 4 (18) 24 (21) 16 (17) 9 (18) 25 (22) 23 (20) 2 (16) 20 (19) 18 (19) 2 (19)”
InfluentialTehrani, M., Krummenauer, F., Mann, W. J., et al. (2004) · PubMed · doi:10.5301/ejo.2008.2576 · Cited by 33
Kosinski, M. R., Bjørner, J. B., Ware, J. E., Batenhorst, A. S., & Cady, R. K. (2003) · Quality of Life Research · doi:10.1023/a:1026111029376 · Cited by 31 · cited 2×
“This comparison was made with the relative validity index, which is a standard measure applied in psychometric comparisons between different measurements of identical concepts (41, 42).”
MethodWatt, T., Groenvold, M., Hegedüs, L., Bonnema, S. J., Rasmussen, Å. K., Feldt-Rasmussen, U., & Bjorner, J. B. (2014) · Quality of Life Research · doi:10.1007/s11136-013-0462-1 · Cited by 30
Self-citationQuality: Its Definition and Measurement As Applied to the Medically Ill
Barofsky, I. (2011) · doi:10.1007/978-1-4419-9819-4 · Cited by 29
Cited by
Gharib, H., Papini, E., Garber, J. R., Duick, D. S., Harrell, R. M., Hegedus, L., Paschke, R., Valcavi, R., & Vitti, P. (2016) · Endocrine Practice · doi:10.4158/ep161208.gl · Cited by 1,272
Self-citation2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management
Durante, C., Hegedüs, L., Czarniecka, A., Paschke, R., Russ, G., Schmitt, F., Soares, P., Solymosi, T., & Papini, E. (2023) · European Thyroid Journal · doi:10.1530/etj-23-0067 · Cited by 425
“This should take into consideration pre-treatment symptomatology, ideally including a thyroid specific patient-reported outcome (PRO) (21), which has been cross-culturally validated (22) and for which instrument minimally important change in the quality of life has been determined (23), allowing…”
BackgroundInfluentialSelf-citationDavies, T. F., Andersen, S., Latif, R., Nagayama, Y., Barbesino, G., Brito, M., Eckstein, A. K., Stagnaro-Green, A., & Kahaly, G. J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0184-y · Cited by 398
Chaker, L., Razvi, S., Bensenor, I. M., Azizi, F., Pearce, E. N., & Peeters, R. P. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00357-7 · Cited by 330
Selenium in thyroid disorders—essential knowledge for clinicians
Winther, K. H., Rayman, M. P., Bonnema, S. J., & Hegedüs, L. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0311-6 · Cited by 288
Self-citation
Metadata
- Authors
- Watt, T., Cramon, P., Hegedüs, L., Bjorner, J. B., Bonnema, S. J., Rasmussen, Å. K., Feldt-Rasmussen, U., & Groenvold, M.
- Affiliations
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- Odense University Hospital (DK)
- Corresponding author
- Watt, Torquil
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2014-10
- Volume
- 99
- Issue
- 10
- Pages
- 3708-3717
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2123438362
- Cited by
- 152
- References
- 49
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 9 · 2023: 15 · 2022: 22 · 2021: 20 · 2020: 11 · 2019: 12 · 2018: 18 · 2017: 11 · 2016: 6 · 2015: 5 · 2014: 3
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- quality of life, responsiveness, patient-reported outcome measures, hyperthyroidism, hypothyroidism, nontoxic goiter, SF-36 Health Survey, thyroid dysfunction, treatment effect detection, goiter surgery, radioiodine therapy
- MeSH terms
- Adult, Aged, Female, Goiter, Health Surveys, Humans, Hyperthyroidism, Hypothyroidism, Male, Mental Health, Middle Aged, Psychometrics, Quality of Life, Treatment Outcome, Graves Ophthalmopathy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.